Breast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone Scintigraphy

Association of Breast Cancer Molecular Subtypes With Patterns of Skeletal Metastases on Bone Scintigraphy

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07750340

Enrollment

100

Registered

2026-08-06

Start date

2026-08-01

Completion date

2027-09-01

Last updated

2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Bone Scintigraphy, Molecular Subtypes, Technetium Tc 99m MDP, Bone Metastases, Breast Cancer

Brief summary

The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy. The study will include adult male and female patients aged 18 to 80 years with histopathologically confirmed breast cancer who are referred for whole-body bone scintigraphy. The main questions it aims to answer are: * What is the frequency and pattern of skeletal metastases across different breast cancer molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Triple-Negative) on bone scintigraphy? * How do nuclear medicine scintigraphic findings correlate with tumor biomarker profiles? Researchers will compare imaging patterns among the different molecular subtype groups to determine if specific biomarker profiles correlate with distinct bone metastatic behaviors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients of both sexes (females and males) with a confirmed histopathological diagnosis of breast cancer, including all major histological types: Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), other mixed or less common epithelial variants. * Patient's age ranging from 18 to 80 years. * Available immunohistochemical (IHC) profiles from the primary breast tumor biopsy or surgery, covering all molecular subtypes including; Luminal A: (ER-positive, PR-positive, HER2-negative, and low Ki-67 index). Luminal B: (ER-positive, PR-variable, HER2-variable "either positive or negative", and high Ki-67 index). HER2-enriched: (ER-negative, PR-negative, and HER2-positive). Triple-Negative breast cancer (TNBC): (no ER, PR or HER2 expression). * Patients referred for bone scintigraphy as part of initial staging, follow-up, or due to clinical suspicion of bone metastasis.

Exclusion criteria

* Patients with other primary malignancies (to avoid confusion regarding the origin of bone metastases). * Patients with incomplete medical records or unavailable immunohistochemical data. * Pregnant female patients. * Patients aged under 18 years old.

Design outcomes

Primary

Measure	Time frame	Description
Presence of skeletal metastases on Tc-99m MDP whole-body bone scintigraphy.	Baseline	Number of participants with skeletal metastases detected by Tc-99m MDP whole-body bone scintigraphy according to breast cancer molecular subtype.
Anatomical distribution of skeletal metastases.	Baseline	Anatomical distribution of skeletal metastases (axial skeleton, appendicular skeleton or mixed) according to breast cancer molecular subtype.

Countries

Egypt

Contacts

CONTACTReham S Mohamed

Reham.Soltan@med.sohag.edu.eg+20 1064214014

PRINCIPAL_INVESTIGATORReham S Mohamed

Faculty of medicine sohag university

Outcome results